Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Stable Type 1 or Type 2 diabetes mellitus~* Visual impairment due to focal or diffuse DME in at least one eye~Exclusion Criteria:~* Active conditions in the study eye that could prevent the improvement of visual acuity on study treatment~* Active eye infection or inflammation~* History of stroke, renal failure or uncontrolled hypertension~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination Therapy (Type: EXPERIMENTAL): Participants received ranibizumab intravitreal injection and laser photocoagulation treatments
- Ranibizumab Monotherapy (Type: EXPERIMENTAL): Participants received ranibizumab intravitreal injection therapy only
- Laser Monotherapy (Type: ACTIVE_COMPARATOR): Participants received Laser photocoagulation therapy only

Based on this trial design, predict the completion outcome and termination type (if applicable).